PPT-ADNI Biomarker Core update

Leslie M Shaw and John Q Trojanowski WW ADNI meeting Chicago July 20 2018 CSF Ser Pla TOTAL ADNI 1 Primary Biofluids Collected 1118 9756 10874 ADNI 1 Aliquots in Bank 24934. . Arg. -ADNI. Gustavo E. Sevlever . , Ricardo . F. . Allegri (. *. ), . Silvia Vázquez, Deborah R. . Gustafson. , . Salvador M. Guinjoan, . and Arg-ADNI group.. Memory and Aging Center. Institute for Neurological Research . Biomarker Potential and . Limitations of . Circulating miRNA. Performed by the . Data Management . a. nd Resource Repository (DMRR). ERCC . D. ata Analysis. 1. Williams Z., et al. . (. 2013. ) Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations. MBBS (Hons), . MMedSci. (. Clin. . Epid. ), . MBiostat. , PhD, FRACP. Biomarker-Based Clinical Trials: Practical and Design Considerations. Biomarker. “Any characteristic that can be objectively measured as an indicator of normal or pathological biological processes or the response to a therapy”. Worldwide Trends . 2014. What is a Biomarker?. Worldwide Trends. 2014. What is a Biomarker?. A biological marker, better known as a “biomarker”, is a characteristic . that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic . Not Quite Ready . for Prime Time. Scott Kopetz, MD, PhD. . Department of GI Medical Oncology. MD Anderson Cancer Center. NOT YET. YES. Individual Biomarkers versus . Molecular Subtypes. Individual biomarkers:. Andy Saykin. WW-ADNI Meeting. London, UK. July 14, 2017. asaykin@iupui.edu. Overview and 2017 Updates. ADNI-3 sample collection (banked at NCRAD). Longitudinal DNA & RNA (12 new, 79 continuing). Changes in ADNI-3 include PBMC and RBC collection. AAIC 2017. Presenter: Dr. Patricio . Chrem. . On . Behalf of:. Dr. Prof Ricardo Allegri (PI) . Dr. Gustavo Sevlever. July 14. th. , 2017. Arg. -ADNI. Patients’ Flowchart. Patients Screened at FLENI. CRF Completion guidelines. Overview. General CRF . completion. Patient details header. Registration CRF. After registration. Almac. Test Request Form. Blood CRF. Color Sample Requisition Form. Screening and . New . findings and methods for feed engineering to face present and future challenges in salmon . aquaculture. Presenter:. Albert . Caballero Solares, . Ph.D. Collaborators:. X. Xue. 1. , J.R. Hall. 2. John Michael Sauer, PhD. Critical Path Institute’s Predictive Safety Testing Consortium. Tucson, Arizona. jsauer@c-path.org. So you have a biomarker(s) that you want to use for regulatory decision making…now what do you do?. Boston, MA 4/24/2017 . Leslie M Shaw. John Q Trojanowski. New biomarkers in NIA/ADNI/RARC-approved studies . Biomarker. Fluid. #. ADNI study. Investigator. NFL & Tau . diag. /prognosis. Plasma. 3,000+. Mayo. . Cliff Jack. Bret Borowski . Matt Bernstein. Arvin Forghanian-Arani . Jeff Gunter. Dave Jones . Kejal Kantarci. Rob Reid . Denise Reyes . Matt Senjem. Kaely Thostenson. Prashanthi Vemuri . Chad Ward . PhUSE 2014 Paper SP06 Renuka Chinthapally, Cytel Statistical Software & Services Pvt. Ltd., Hyderabad, India ABSTRACT Biomarkers play an important role in the clinical development due to their ability 2 Understanding the biomarker research activity, is critical as multiple stakeholders align themselves with the latest science. CONTENTSFOREWORDBy Edward Abrahams, President, Personalized Medicine Coa